FDA Opens Consultation on Generative AI Medical Device Regulation

The FDA has launched a public consultation to gather input on regulating generative AI technologies in medical devices, aiming to develop clear oversight that balances innovation with patient safety FDA.

On June 4, 2024, the U.S. Food and Drug Administration (FDA) announced an open call for public comments regarding the regulation of generative AI technologies used in medical devices. This consultation targets healthcare providers, technology developers, patients, and other stakeholders, and will remain open for 60 days. The FDA’s action signals a move toward establishing formal guidance for the use of generative AI in diagnostics, treatment planning, and other clinical applications FDA.

Generative AI, which can autonomously create new content such as diagnostic images or treatment recommendations, presents unique regulatory challenges compared to traditional “locked” AI systems. For regulated healthcare enterprises, this consultation is a critical step toward clarifying how the FDA will interpret and enforce requirements under the Federal Food, Drug, and Cosmetic Act (FD&C Act), as well as how these rules will interact with existing frameworks like the EU AI Act and the NIST AI Risk Management Framework HealthTech Magazine. The FDA’s move is particularly relevant for organizations developing or deploying AI-enabled devices that could impact patient safety, data integrity, and clinical workflows.

CTOs, CISOs, and Compliance Officers in health systems and medical device companies should closely monitor this consultation and prepare to adapt their AI governance, validation, and documentation practices. Over the next 30-90 days, enterprise leaders should review their current and planned generative AI deployments for alignment with anticipated FDA requirements, participate in the consultation process, and assess potential impacts on product development timelines and regulatory submissions FDA.

What This Means for Enterprise AI

The FDA’s consultation is likely to result in new or updated guidance that explicitly addresses the risks and validation requirements unique to generative AI, such as output unpredictability, data provenance, and continuous learning HealthTech Magazine. Enterprises should expect the FDA to require enhanced transparency, explainability, and post-market surveillance for generative AI features, aligning with broader regulatory trends under the EU AI Act and NIST AI RMF NIST. Compliance teams should begin mapping their generative AI systems to these frameworks and prepare for more rigorous evidence collection around model performance, bias mitigation, and human oversight.

For organizations in regulated healthcare, this is a critical window to influence policy by submitting feedback and use cases to the FDA. Early engagement may help shape pragmatic requirements and avoid regulatory surprises. CTOs should also anticipate that future FDA submissions for generative AI-enabled devices will require more detailed technical documentation, including model update protocols and risk mitigation strategies.